An Australian stem cell and regenerative medicine company

October 10, 2023

2023 Alliance for Regenerative Medicine Meeting on the Mesa

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Cynata CEO Dr Kilian Kelly presented on Cynata’s Cymerus technology and provided an update on the Company’s robust clinical pipeline.

Watch the presentation here

September 20, 2023

The Watchlist webinar

In case you missed it, Cynata CEO & MD Dr Kilian Kelly provided investors with an update on The Company’s ongoing active trials and its priorities for the next 12 months, including what investors should be looking for. 

Watch his presentation below.

August 22, 2023

Interview with Kalkine Media

Following its strategic review, and off the back of two critical clinical trial updates - the opening of Cynata’s acute Graft-versus-host disease trial for enrolment and the approval of its Phase 1 clinical trial in kidney transplant patients - CEO Dr Kilian Kelly sat down with Kalkine Media to discuss the milestones. 

Watch the interview here 

August 21, 2023

Cynata receives approval for trial in kidney transplant patients

Cynata has received regulatory approval from the Competent (regulatory) Authority in the Netherlands for a Phase 1 trial of CYP-001 in kidney transplant patients. Professor Rabelink, who is leading the trial, said it aims to alleviate anti-rejection drug side effects which would be of huge benefit to transplant patients as the side effects of immunosuppressants can be very devastating.

Read the full article here

July 27, 2023

Investor Webinar Presentation

Listen to Cynata’s CEO and MD, Dr Kilian Kelly, provide an overview of the recently completed strategic review, and responses to investors’ questions.


Listen Here